MPT: Mixed Results for Shorter DAPT in ACS Patients

ACC Conference Reporter

ACC.18 | ORLANDO, FL — Although a shorter duration of dual antiplatelet therapy (DAPT) was non-inferior to the standard regimen among acute coronary syndrome (ACS) patients getting drug-eluting stents (DES) in the SMART-DATE trial, a signal of excess MIs led investigators to caution against the interpretation that the two are equally safe. Read More >>>

Keywords: ACC18, ACC Annual Scientific Session

< Back to Listings